Clinical significance of telomerase activity in basal cell carcinomas and in tumour-free surgical margins

Fabricius, Eva‐Maria; Bezeluk, Aleksej; Kruse-Boitschenko, Ute; Wildner, Gustav‐Paul; Klein, Martin

doi:10.3892/ijo.23.5.1389

Cited by 6 publications

(21 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In previous examinations we had only been able to prove a limited correlation between telomerase activity and lymphocyte infiltration in tumor margin tissues (24,(60)(61)(62)(63). We expanded our investigation and incorporated an anti-nucleolin antibody (Ab 13) to clarify this issue since the monoclonal anti-hTERT antibody (clone 44F12, code NCL-hTERT, Table II, Ab 3) was classified in the paper by Wu et al (64) as an antibody against nucleolin.…”

Section: Immunohistochemistry and Immunoreactive Score Values (Irs)mentioning

confidence: 99%

“…We used the frozen sections from basal cell carcinomas in which we had previously demonstrated telomerase activity in PCR ELISA (24,49). As already reported (52), we optimized nuclear hTERT demonstration by working with four commercially available anti-hTERT antibodies, the three polyclonal rabbit antibodies, code PC 563 from Oncogene, EST21-A from Alpha Diagnostics and code 582005 by Calbiochem and the monoclonal murine antibody clone 44F12 by NovoCastra.…”

Section: Immunohistochemistry and Immunoreactive Score Values (Irs)mentioning

confidence: 99%

“…Many investigations have demonstrated telomerase activity in basal cell carcinomas and their tumor margins (23)(24)(25)(26)(38)(39)(40)(41)(42)(43)(44)(45)(46)(47)(48)(49)(50)(51). In our BCC-study we looked for a difference in telomerase activity between BCC-free tumor margin tissue of head and neck tumors, the tumor itself and control tissue (24,26,49). Proof of telomerase by PCR provides no information about telomerase expression in the isolated cells, but immunohistochemistry is well suited for the in situ presentation of telomerase positive cells, providing that INTERNATIONAL JOURNAL OF ONCOLOGY 35: 1377ONCOLOGY 35: -1394ONCOLOGY 35: , 2009 Localization of telomerase hTERT protein in frozen sections of basal cell carcinomas (BCC) and tumor margin tissues suitable antibodies are available.…”

Section: Introductionmentioning

confidence: 99%

“…Epidemiological data (5,6,8,9,(11)(12)(13)(14)(15)(16) show clearly that ultraviolet (UV) radiation, particularly UVB, is an essential etiological factor in the carcinogenesis of skin tumors. UV exposure is a chronic oxidative stress (17) that causes DNA damage with specific mutations of suppressor genes such as p53 (14,16,(18)(19)(20)(21)(22): it is activated along with telomerase (23)(24)(25)(26)(27). Molecular changes in the skin are associated with local cell proliferation.…”

Section: Introductionmentioning

confidence: 99%

“…An important cause of this is field cancerization (28) in the area around the BCC (29)(30)(31)(32). Studies are in progress to find the best suited molecular or immunohistochemical markers for characterizing tumor-free margin tissue (8,12,13,24,(33)(34)(35)(36).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Localization of telomerase hTERT protein in frozen sections of basal cell carcinomas (BCC) and tumor margin tissues

Fabricius

Kruse-Boitschenko²,

Khoury³

et al. 2009

Int J Oncol

View full text Add to dashboard Cite

Abstract.In previous studies we demonstrated telomerase activity in frozen tissues from BCC and their tumor-free margins by the PCR ELISA. In this study we examined in the same frozen sections immunohistochemical presence of hTERT in the nucleus. After fixation in acetone and methanol followed by steaming we used for visualization the antigenantibody reactions by APAAP. This was the best method of preparation of the frozen sections in our preliminary hTERT-study with squamous cell carcinomas. This study was supplemented with antibodies against Ki-67, nucleolin, common leucocyte antigen CD45 and mutated p53. The immunoreactive scores were determined and included the comparison with telomerase activity. The investigation of hTERT expression was performed in the tissues of 41 patients with BCC and control tissues of 14 patients without tumor. Eleven commercial antibodies were used for a nuclear staining of hTERT expression. With the anti-hTERT antibodies we looked for both satisfactory distribution and intensity of immunohistochemical labeling in the carcinomas and in the squamous epithelia of the tumor centers, of the tumor-free margins and of the control tissues. The hTERT expression in the BCC was distributed heterogeneously. The score values established by the anti-hTERT antibodies used were variably or significantly increased. In the stroma they tended to be negative, so we disregarded stroma hTERT. Proof of hTERT did not differ uniformly from telomerase activity. We compared the high with the lower median hTERT values in the Kaplan-Meier curve. Patients with lower hTERT scores in the center or tumor margin as shown by some of the antibodies suffered relapse earlier. Finally, we compared the hTERT expression in BCC tissues with the hTERT scores in HNSCC tissues from our previous study. Only one anti-hTERT antibody (our Ab 7) yielded significantly higher scores in BCC than in HNSCC.

show abstract